Details of Xenobiotics-DME Interaction (XEOTIC)

General Information of Drug-Metabolizing Enzyme (DME ID: DME0409)
DME Name Carbonic anhydrase II (CA2), Homo sapiens DME Info
UniProt ID
CAH2_HUMAN
EC Number    EC: 4.2.1.1     (Click to Show/Hide the Complete EC Tree)
Lyases
Carbon-oxygen lyase
Hydro-lyase
EC: 4.2.1.1
Lineage    Species: Homo sapiens     (Click to Show/Hide the Complete Species Lineage)
Kingdom: Metazoa
Phylum: Chordata
Class: Mammalia
Order: Primates
Family: Hominidae
Genus: Homo
Species: Homo sapiens
Interactome
Interactions between Xenobiotics and DME (XEOTIC)
      Fungicide(s), Herbicide(s) or Insecticide(s)
                  Herbicide Click to Show/Hide the Full List of Xenobiotics:        1 Xenobiotics
                              Oryzalin Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00977   XEOTIC Info Gene Form Protein
                                 Classification Herbicide
                                 DME Modulation Oryzalin inhibits the drug-metabolizing activity of DME CA2 [1]
      Health or Environmental Toxicant(s)
                  Carcinogen Click to Show/Hide the Full List of Xenobiotics:        1 Xenobiotics
                              Benzo(a)pyrene Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00898   XEOTIC Info Gene Form mRNA
                                 Classification Carcinogen
                                 DME Modulation Benzo(a)pyrene up-regulates the expression of DME CA2 [2]
                  Environmental Pollutant Click to Show/Hide the Full List of Xenobiotics:        2 Xenobiotics
                              2,6-di-tert-butylphenol Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01115   XEOTIC Info Gene Form Protein
                                 Classification Environmental Pollutant
                                 DME Modulation 2,6-di-tert-butylphenol inhibits the drug-metabolizing activity of DME CA2 (Ki = 0.51 microM) [3]
                              Dimethyl amines Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01005   XEOTIC Info Gene Form Protein
                                 Classification Environmental Pollutant
                                 DME Modulation Dimethyl amines inhibits the drug-metabolizing activity of DME CA2 [4]
                  Health Hazard/Toxicant Click to Show/Hide the Full List of Xenobiotics:        5 Xenobiotics
                              1,2,4-triazole Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01087   XEOTIC Info Gene Form Protein
                                 Classification Health Hazard
                                 DME Modulation 1,2,4-triazole inhibits the drug-metabolizing activity of DME CA2 [5]
                              Butyraldehyde Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00999   XEOTIC Info Gene Form mRNA
                                 Classification Health Hazard
                                 DME Modulation Butyraldehyde up-regulates the expression of DME CA2 [6]
                              Chloric acid Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01001   XEOTIC Info Gene Form Protein
                                 Classification Health Hazard
                                 DME Modulation Chloric acid inhibits the drug-metabolizing activity of DME CA2 (Ki = 850 microM) [7]
                              Coumarin Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00879   XEOTIC Info Gene Form Protein
                                 Classification Health Hazard
                                 DME Modulation Coumarin inhibits the drug-metabolizing activity of DME CA2 (Ki = 9.2 microM) [8]
                              Lead Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01505   XEOTIC Info Gene Form Protein
                                 Classification Health Hazard
                                 DME Modulation Lead inhibits the drug-metabolizing activity of DME CA2 [9]
      Natural Product(s), Extract(s) or Medicine(s)
                  Natural Mixture Click to Show/Hide the Full List of Xenobiotics:        1 Xenobiotics
                              Flavonoids Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00858   XEOTIC Info Gene Form Protein
                                 Classification Natural Mixture
                                 DME Modulation Flavonoids inhibits the drug-metabolizing activity of DME CA2 [10]
                  Natural Product Click to Show/Hide the Full List of Xenobiotics:        4 Xenobiotics
                              Anthocyanins Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01522   XEOTIC Info Gene Form Protein
                                 Classification Natural Product
                                 DME Modulation Anthocyanins inhibits the drug-metabolizing activity of DME CA2 [10]
                              Malvidin-3-glucoside Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01562   XEOTIC Info Gene Form Protein
                                 Classification Natural Product
                                 DME Modulation Malvidin-3-glucoside inhibits the drug-metabolizing activity of DME CA2 [11]
                              Synephrine Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00908   XEOTIC Info Gene Form Protein
                                 Classification Natural Product
                                 DME Modulation Synephrine inhibits the drug-metabolizing activity of DME CA2 [12]
                              Tunicamycin A Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01494   XEOTIC Info Gene Form mRNA
                                 Classification Natural Product
                                 DME Modulation Tunicamycin A inhibits the expression of DME CA2 [13], [14]
      Pharmaceutical Agent(s)
                  Approved/Marketed Drug Click to Show/Hide the Full List of Xenobiotics:      28 Xenobiotics
                              Acetazolamide Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00002   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Acetazolamide inhibits the drug-metabolizing activity of DME CA2 (IC50 < 0.01 microM) [15]
                              Alitretinoin Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00167   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Alitretinoin induces the drug-metabolizing activity of DME CA2 [16]
                              Brinzolamide Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00141   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Brinzolamide inhibits the drug-metabolizing activity of DME CA2 (IC50 = 0.0032 microM) [17]
                              Calcitriol Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00184   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Calcitriol up-regulates the expression of DME CA2 [18], [19]
                              Celecoxib Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00013   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Celecoxib inhibits the drug-metabolizing activity of DME CA2 (IC50 = 0.021 microM) [20]
                              Copper sulfate Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00117   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Copper sulfate up-regulates the expression of DME CA2 [21]
                              Cyclophosphamide Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00018   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Cyclophosphamide inhibits the expression of DME CA2 [22]
                              Cyclosporine Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00241   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Cyclosporine inhibits the expression of DME CA2 [2]
                              Dexamethasone Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00088   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Dexamethasone up-regulates the expression of DME CA2 [23]
                              Dichlorphenamide Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00025   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Dichlorphenamide inhibits the drug-metabolizing activity of DME CA2 (IC50 = 0.038 microM) [24], [25]
                              Diethylstilbestrol Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00166   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Diethylstilbestrol up-regulates the expression of DME CA2 [26]
                              Dorzolamide hydrochloride Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00291   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Dorzolamide hydrochloride inhibits the drug-metabolizing activity of DME CA2 (IC50 < 0.002 microM) [27]
                              Enalapril Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00356   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Enalapril inhibits the drug-metabolizing activity of DME CA2 [28]
                              Epinephrine Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00265   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Epinephrine up-regulates the expression of DME CA2 [29]
                              Estradiol Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00090   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Estradiol up-regulates the expression of DME CA2 [30], [31]
                              Ethinyl estradiol Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00267   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Ethinyl estradiol up-regulates the expression of DME CA2 [32]
                              Ethoxzolamide Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00414   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Ethoxzolamide inhibits the drug-metabolizing activity of DME CA2 (IC50 = 0.0003 microM) [33]
                              Furosemide Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00040   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Furosemide inhibits the drug-metabolizing activity of DME CA2 (Ki = 0.065 microM) [34]
                              Indomethacin Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00047   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Indomethacin induces the drug-metabolizing activity of DME CA2 [35]
                              Methazolamide Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00061   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Methazolamide inhibits the drug-metabolizing activity of DME CA2 (IC50 = 0.0048 microM) [36]
                              Progesterone Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00094   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Progesterone inhibits the drug-metabolizing activity of DME CA2 [37]
                              Propofol Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00075   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Propofol inhibits the drug-metabolizing activity of DME CA2 (Ki = 19.5 microM) [3]
                              Sulfonamide Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00424   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Sulfonamide inhibits the drug-metabolizing activity of DME CA2 [38]
                              Titanium dioxide Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00425   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Titanium dioxide up-regulates the expression of DME CA2 [39], [40]
                              Topiramate Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00189   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Topiramate inhibits the drug-metabolizing activity of DME CA2 (IC50 = 0.005 microM) [25]
                              Valdecoxib Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00150   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Valdecoxib inhibits the drug-metabolizing activity of DME CA2 (IC50 = 0.043 microM) [24], [25]
                              Valproic acid Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00029   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Valproic acid up-regulates the expression of DME CA2 [41]
                              Sulpiride Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00484   XEOTIC Info Gene Form Protein
                                 Classification Drug Marketed but not Approved by US FDA
                                 DME Modulation Sulpiride inhibits the drug-metabolizing activity of DME CA2 (IC50 = 0.04 microM) [25]
                  Drug in Phase 3 Clinical Trial Click to Show/Hide the Full List of Xenobiotics:        3 Xenobiotics
                              Afimoxifene Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00610   XEOTIC Info Gene Form mRNA
                                 Classification Highest Clinical Status: Phase 3
                                 DME Modulation Afimoxifene up-regulates the expression of DME CA2 [42]
                              Guaiacol Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00566   XEOTIC Info Gene Form Protein
                                 Classification Highest Clinical Status: Phase 3
                                 DME Modulation Guaiacol inhibits the drug-metabolizing activity of DME CA2 (Ki = 2.94 microM) [3]
                              Seocalcitol Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00652   XEOTIC Info Gene Form mRNA
                                 Classification Highest Clinical Status: Phase 3
                                 DME Modulation Seocalcitol up-regulates the expression of DME CA2 [43]
                  Drug in Phase 2 Clinical Trial Click to Show/Hide the Full List of Xenobiotics:        5 Xenobiotics
                              Bisphenol A Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO01226   XEOTIC Info Gene Form mRNA
                                 Classification Highest Clinical Status: Phase 2
                                 DME Modulation Bisphenol A up-regulates the expression of DME CA2 [31]
                              Chalcone Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01242   XEOTIC Info Gene Form Protein
                                 Classification Highest Clinical Status: Phase 2
                                 DME Modulation Chalcone inhibits the drug-metabolizing activity of DME CA2 [44]
                              Genistein Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00557   XEOTIC Info Gene Form mRNA
                                 Classification Highest Clinical Status: Phase 2
                                 DME Modulation Genistein up-regulates the expression of DME CA2 [45]
                              Indisulam Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01387   XEOTIC Info Gene Form Protein
                                 Classification Highest Clinical Status: Phase 2
                                 DME Modulation Indisulam inhibits the drug-metabolizing activity of DME CA2 [46]
                              Irosustat Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00651   XEOTIC Info Gene Form Protein
                                 Classification Highest Clinical Status: Phase 2
                                 DME Modulation Irosustat inhibits the drug-metabolizing activity of DME CA2 (IC50 = 0.017 microM) [47]
                  Drug in Phase 1 Clinical Trial Click to Show/Hide the Full List of Xenobiotics:        3 Xenobiotics
                              Butylated hydroxytoluene Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00601   XEOTIC Info Gene Form Protein
                                 Classification Highest Clinical Status: Phase 1
                                 DME Modulation Butylated hydroxytoluene inhibits the drug-metabolizing activity of DME CA2 (Ki = 0.63 microM) [3]
                              Dinitrochlorobenzene Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00571   XEOTIC Info Gene Form mRNA
                                 Classification Highest Clinical Status: Phase 1
                                 DME Modulation Dinitrochlorobenzene inhibits the expression of DME CA2 [48]
                              Quercetin Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00538   XEOTIC Info Gene Form Protein
                                 Classification Highest Clinical Status: Phase 1
                                 DME Modulation Quercetin induces the drug-metabolizing activity of DME CA2 [49]
                  Preclinical/Patented Drug Click to Show/Hide the Full List of Xenobiotics:        1 Xenobiotics
                              STX140 Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00716   XEOTIC Info Gene Form Protein
                                 Classification Drug in Preclinical Study
                                 DME Modulation STX140 inhibits the drug-metabolizing activity of DME CA2 (IC50 = 0.379 microM) [50], [51]
                  Investigative Agent Click to Show/Hide the Full List of Xenobiotics:        2 Xenobiotics
                              Benzolamide Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01216   XEOTIC Info Gene Form Protein
                                 Classification Investigative Agent
                                 DME Modulation Benzolamide inhibits the drug-metabolizing activity of DME CA2 (Ki = 0.009 microM) [52]
                              Thioxolone Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01486   XEOTIC Info Gene Form Protein
                                 Classification Investigative Agent
                                 DME Modulation Thioxolone inhibits the drug-metabolizing activity of DME CA2 (IC50 = 1.77 microM) [53]
      Other Chemical Compound(s) or Element(s)
                  Chemical Compound Click to Show/Hide the Full List of Xenobiotics:        4 Xenobiotics
                              Iodate Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00800   XEOTIC Info Gene Form Protein
                                 Classification Chemical Compound
                                 DME Modulation Iodate inhibits the drug-metabolizing activity of DME CA2 [7]
                              Nitric acid Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01017   XEOTIC Info Gene Form Protein
                                 Classification Chemical Compound
                                 DME Modulation Nitric acid inhibits the drug-metabolizing activity of DME CA2 (Ki = 35000 microM) [54]
                              Sulfamic acid Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00771   XEOTIC Info Gene Form Protein
                                 Classification Chemical Compound
                                 DME Modulation Sulfamic acid inhibits the drug-metabolizing activity of DME CA2 (Ki = 0.00039 microM) [54]
                              Thiophenes Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00781   XEOTIC Info Gene Form mRNA
                                 Classification Chemical Compound
                                 DME Modulation Thiophenes inhibits the expression of DME CA2 [55]
References
1 The extra virgin olive oil phenolic oleacein is a dual substrate-inhibitor of catechol-O-methyltransferase. Food Chem Toxicol. 2019 Jun;128:35-45.
2 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
3 Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols bioorg. Med Chem. 2009 Apr 15;17(8):3207-11.
4 Synthesis and discovery of potent carbonic anhydrase, acetylcholinesterase, butyrylcholinesterase, and alpha-glycosidase enzymes inhibitors: the novel N,N'-bis-cyanomethylamine and alkoxymethylamine derivatives. J Biochem Mol Toxicol. 2018 Apr;32(4):e22042.
5 In vitro cytotoxic and in vivo antitumoral activities of some aminomethyl derivatives of 2,4-dihydro-3H-1,2,4-triazole-3-thiones-Evaluation of their acetylcholinesterase and carbonic anhydrase enzymes inhibition profiles. J Biochem Mol Toxicol. 2018 Oct 28:e22239.
6 Integrated analysis of microRNA and mRNA expression profiles highlights aldehyde-induced inflammatory responses in cells relevant for lung toxicity. Toxicology. 2015 Aug 6;334:111-21.
7 Carbonic anhydrase inhibitorsInhibition of isozymes I, II, IV, V, and IX with anions isosteric and isoelectronic with sulfate, nitrate, and carbonate. Bioorg Med Chem Lett. 2005 Feb 1;15(3):567-71.
8 Thioxocoumarins show an alternative carbonic anhydrase inhibition mechanism compared to coumarins. J Med Chem. 2016 Jan 14;59(1):462-73.
9 In vitro inhibitory effects of some heavy metals on human erythrocyte carbonic anhydrases. J Enzyme Inhib Med Chem. 2007 Dec;22(6):745-50.
10 Inhibition properties of some flavonoids on carbonic anhydrase I and II isoenzymes purified from human erythrocytes. J Biochem Mol Toxicol. 2017 Sep;31(9).
11 Characterization of human cytochrome P450 induction by pesticides. Toxicology. 2012 Mar 29;294(1):17-26.
12 Assessment of the inhibitory effects and molecular docking of some sulfonamides on human serum paraoxonase 1. J Biochem Mol Toxicol. 2017 Oct;31(10).
13 Defensive and adverse energy-related molecular responses precede tris (1, 3-dichloro-2-propyl) phosphate cytotoxicity. J Appl Toxicol. 2016 May;36(5):649-58.
14 Endocrine disruption potentials of organophosphate flame retardants and related mechanisms in H295R and MVLN cell lines and in zebrafish. Aquat Toxicol. 2012 Jun 15;114-115:173-81.
15 Novel, broad-spectrum anticonvulsants containing a sulfamide group: pharmacological properties of (S)-N-[(6-chloro-2,3-dihydrobenzo[1,4]dioxin-2-yl)methyl]sulfamide (JNJ-26489112). J Med Chem. 2013 Nov 27;56(22):9019-30.
16 Investigation of the mechanisms by which EB1089 abrogates apoptosis induced by 9-cis retinoic acid in pancreatic cancer cells. Pancreas. 2006 Jan;32(1):93-100.
17 Structural aspects of isozyme selectivity in the binding of inhibitors to carbonic anhydrases II and IV. J Med Chem. 2002 Feb 14;45(4):888-93.
18 Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
19 Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
20 Designed multiple ligandsAn emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43.
21 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
22 Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors. Leuk Res. 2007 Nov;31(11):1511-20.
23 Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
24 Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J Med Chem. 2004 Jan 29;47(3):550-7.
25 Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with the antipsychotic drug sulpiride. Bioorg Med Chem Lett. 2004 Jan 19;14(2):337-41.
26 Gene expression profiling in Ishikawa cells: a fingerprint for estrogen active compounds. Toxicol Appl Pharmacol. 2009 Apr 1;236(1):85-96.
27 Thioether benzenesulfonamide inhibitors of carbonic anhydrases II and IV: structure-based drug design, synthesis, and biological evaluation. Bioorg Med Chem. 2010 May 1;18(9):3307-19.
28 Captopril/enalapril inhibit promiscuous esterase activity of carbonic anhydrase at micromolar concentrations: An initro study. Chem Biol Interact. 2017 Mar 1;265:24-35.
29 Effects of beta-adrenergic agonists on bone-resorbing activity in human osteoclast-like cells. Biochim Biophys Acta. 2003 May 12;1640(2-3):137-42.
30 Long-term estrogen exposure promotes carcinogen bioactivation, induces persistent changes in gene expression, and enhances the tumorigenicity of MCF-7 human breast cancer cells. Toxicol Appl Pharmacol. 2009 Nov 1;240(3):355-66.
31 Genistein and bisphenol A exposure cause estrogen receptor 1 to bind thousands of sites in a cell type-specific manner. Genome Res. 2012 Nov;22(11):2153-62.
32 The genomic response of a human uterine endometrial adenocarcinoma cell line to 17alpha-ethynyl estradiol. Toxicol Sci. 2009 Jan;107(1):40-55.
33 Discovery of new potent inhibitors for carbonic anhydrase IX by structure-based virtual screening. Bioorg Med Chem Lett. 2013 Jun 15;23(12):3496-9.
34 Carbonic anhydrase inhibitorsComparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21.
35 Indomethacin activates carbonic anhydrase and antagonizes the effect of the specific carbonic anhydrase inhibitor acetazolamide, by a direct mechanism of action. Int J Clin Pharmacol Ther. 2001 Jun;39(6):265-70.
36 Optimization of heterocyclic substituted benzenesulfonamides as novel carbonic anhydrase IX inhibitors and their structure activity relationship. Eur J Med Chem. 2013 Apr;62:597-604.
37 In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations catalyzed by human cytochrome P450 enzymes: a comparison with SKF-525A and ketoconazole. Drug Metab Pharmacokinet. 2003;18(5):287-95.
38 Drug interaction study of flavonoids toward CYP3A4 and their quantitative structure activity relationship (QSAR) analysis for predicting potential effects. Toxicol Lett. 2018 Sep 15;294:27-36.
39 Chemical stresses fail to mimic the unfolded protein response resulting from luminal load with unfolded polypeptides. J Biol Chem. 2018 Apr 13;293(15):5600-5612.
40 Cadmium induces transcription independently of intracellular calcium mobilization. PLoS One. 2011;6(6):e20542.
41 Integrated 'omics analysis reveals new drug-induced mitochondrial perturbations in human hepatocytes. Toxicol Lett. 2018 Jun 1;289:1-13.
42 Identification of novel ER-alpha target genes in breast cancer cells: gene- and cell-selective co-regulator recruitment at target promoters determines the response to 17beta-estradiol and tamoxifen. Mol Cell Endocrinol. 2010 Jan 15;314(1):90-100.
43 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
44 Comparison of the inhibitory potential towards carbonic anhydrase, acetylcholinesterase and butyrylcholinesterase of chalcone and chalcone epoxide. J Biochem Mol Toxicol. 2019 Feb;33(2):e22240.
45 Dose- and time-dependent transcriptional response of Ishikawa cells exposed to genistein. Toxicol Sci. 2016 May;151(1):71-87.
46 Xanthohumol attenuates tumour cell-mediated breaching of the lymphendothelial barrier and prevents intravasation and metastasis. Arch Toxicol. 2013 Jul;87(7):1301-12.
47 Docking studies of sulphamate inhibitors of estrone sulphatase in human carbonic anhydrase II. Bioorg Med Chem Lett. 2003 Mar 10;13(5):863-5.
48 Microarray analyses in dendritic cells reveal potential biomarkers for chemical-induced skin sensitization. Mol Immunol. 2007 May;44(12):3222-33.
49 Quercetin, quercetin glycosides and taxifolin differ in their ability to induce AhR activation and CYP1A1 expression in HepG2 cells. Phytother Res. 2012 Nov;26(11):1746-52.
50 2-substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity. J Med Chem. 2006 Dec 28;49(26):7683-96.
51 Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents. J Med Chem. 2008 Mar 13;51(5):1295-308.
52 Sulfonamide inhibition studies of the beta-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae. Bioorg Med Chem. 2016 Mar 1;24(5):1115-20.
53 Carbonic anhydrase inhibitors: thioxolone versus sulfonamides for obtaining isozyme-selective inhibitors? Bioorg Med Chem Lett. 2008 Jul 15;18(14):3938-41.
54 Carbonic anhydrase inhibitorsInhibition studies with anions and sulfonamides of a new cytosolic enzyme from the scleractinian coral Stylophora pistillata. Bioorg Med Chem Lett. 2011 Jan 15;21(2):710-4.
55 Oxidative stress mechanisms do not discriminate between genotoxic and nongenotoxic liver carcinogens. Chem Res Toxicol. 2015 Aug 17;28(8):1636-46.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.